DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1808)

41 Biopharma Reports

  • non-small-cell lung cancer
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is...
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of th......
Immune checkpoint inhibitors have entered multiple oncology indications but...
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansio......
Biomarker-driven prescribing in oncology is playing an increasingly important...
Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSC......
Oncology indications increasingly use predictive biomarkers to guide prescribing...
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into priva......
Oncology indications increasingly use predictive biomarkers to guide prescribing...
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their inco......
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite...
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28......
1 - 20 of 41